Technology | Radiation Dose Management | July 11, 2019

Fluke Biomedical Introduces RaySafe 452 Survey Meter

New versatile meter delivers fast, flat, wide energy response times to ensure accurate, trustworthy radiation data collection

Fluke Biomedical Introduces RaySafe 452 Survey Meter

July 11, 2019 – Radiation measurement often requires different devices for varying applications, adding to the cost and complexity of data collection. The new RaySafe 452 Survey Meter is a versatile, tool that can be used for multiple situations, reducing the number of devices technicians need to carry, learn and calibrate.

The 452 Survey Meter can measure radiation in a wide variety of applications, including wall leakage, scattered radiation in a room, tube leakage, nuclear medicine and control of treated patients. The meter helps technicians:

•   Make data collection accurately and easily with fast response times;

•   Detect variations from background radiation levels due to its high sensitivity;

•   Trust the readings without post-processing of the data due to a flat, wide energy response range; and

•   Easily save data and analyze it later with the automatic saving of dose rate values every second.

The RaySafe 452 features an optimized, modern design that provides a big, clear, easy-to-read display with all the parameters in a single backlit display. Its ergonomic and lightweight design makes it easy to hold, carry and use even over extended periods of time. It has an IP 64 rating so it can easily be cleaned with water without damaging the device.

The survey meter comes with RaySafe View software that makes it easy to transfer data to a PC and log data quickly, easily and efficiently. All data is time stamped and dose rate waveforms can be further analyzed later. Built on the RaySafe X2 technology, the 452 Survey Meter provides peace of mind that the readings collected are accurate.

For more information: www.flukebiomedical.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2  The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ve

 The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Contextual detail and considerations for imaging with CXR (chest radiography) versus CT (computed tomography) are presented in the text. (Pos=positive, Neg=negative, Mod=moderate). [Although not covered by this scenario and not shown in the figure, in the presence of significant resources constraints, there is no role for imaging of patients with mild features of COVID-19.] Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | April 07, 2020
April 7, 2020 — A multinational consens...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Chest CT findings of pediatric patients with COVID-19 on transaxial images. (a) Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe

Chest CT findings of pediatric patients with COVID-19 on transaxial images. Male, 2 months old, 2 days after symptom onset. Patchy ground-glass opacities GGO in the right lower lobe. Image courtesy of Radiology: Cardiothoracic Imaging

News | Coronavirus (COVID-19) | April 06, 2020
April 6, 2020 — Children and teenagers with COVID-19...
Varian received FDA clearance for its Ethos therapy in February 2020. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Varian received FDA clearance for its Ethos therapy in February 2020, shown here displayed for the first time at ASTRO 2019. It is an adaptive intelligence solution that uses onboard AI in the treatment system to take the cone beam CT imaging on the system, compare it to the treatment plan and deliver an entire adaptive treatment plan in a typical 15-minute treatment time slot, from patient setup through treatment delivery.

Feature | Treatment Planning | April 03, 2020 | Dave Fornell, Editor
The traditional treatment planning process takes days to create an optimized radiation therapy delivery plan, but new
Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Rising concerns over radiation overexposure teamed with a growing focus on improving the quality of patient care are two key drivers of today’s radiation dose management market. 

Feature | Radiation Dose Management | April 02, 2020 | By Melinda Taschetta-Millane
Rising concerns over...
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 A brief article from Henry Ford Health System in Detroit, published today in Radiology, reports on the first presumptive case of COVID-19–associated acute necrotizing hemorrhagic encephalopathy.

A, Image from noncontrast head CT demonstrates symmetric hypoattenuation within the bilateral medial thalami (arrows). B, Axial CT venogram demonstrates patency of the cerebral venous vasculature, including the internal cerebral veins (arrows). C, Coronal reformat of aCT angiogram demonstrates normal appearance of the basilar artery and proximal posterior cerebral arteries. Image courtesy of the Radiological Society of North America (RSNA)

News | Coronavirus (COVID-19) | March 31, 2020
March 31, 2020 — A brief article fr
RSNA's open data repository will compile images and correlative data to create a comprehensive source for COVID-19 research and education efforts #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2
News | Coronavirus (COVID-19) | March 30, 2020
March 30, 2020 — The medical imaging community around the world is uniting to help address the...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Typical CT imaging features for COVID-19. Unenhanced, thin-section axial images of the lungs in a 52-year-old man with a positive RT-PCR (A-D) show bilateral, multifocal rounded (asterisks) and peripheral GGO (arrows) with superimposed interlobular septal thickening and visible intralobular lines (“crazy-paving”). Routine screening CT for diagnosis or exclusion of COVID-19 is currently not recommended by most professional organizations or the US Centers for Disease Control and Prevention. Image courtesy of RSNA

News | Coronavirus (COVID-19) | March 26, 2020
March 26, 2020 — The Radiological Society of North America (RSNA
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Representative examples of the attention heatmaps generated using Grad-CAM method for (a) COVID-19, (b) CAP, and (c) Non-Pneumonia. The heatmaps are standard Jet colormap and overlapped on the original image, the red color highlights the activation region associated with the predicted class. COVID-19 = coronavirus disease 2019, CAP = community acquired pneumonia. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | March 20, 2020
March 20, 2020 — An arti...